A novel trial evaluated the impact of Levagen+® Palmitoylethanolamide (PEA) supplementation on cognitive function and BDNF levels in healthy adults. Over a 6-week period, participants received either PEA or a placebo in a double-blinded crossover study. Results indicated a significant rise in serum BDNF levels post-PEA supplementation compared to placebo, alongside enhanced memory performance demonstrated by improved first success and reduced errors on cognitive tests. This study marks the first to demonstrate the cognitive benefits of Levagen+® PEA, suggesting its potential as a valuable intervention for cognitive enhancement, supported by elevated levels of the neurotrophic marker BDNF
Home » Unlocking Cognitive Potential: Palmitoylethanolamide Supplementation Enhances Memory and BDNF Levels in Healthy Adults
Unlocking Cognitive Potential: Palmitoylethanolamide Supplementation Enhances Memory and BDNF Levels in Healthy Adults
Facebook
Twitter
LinkedIn
Email
WhatsApp
Facebook
Twitter
LinkedIn
Email
WhatsApp
Related Shorts
A Little Fat Goes a Long Way for Malaria Treatment
October 21, 2026
Grapefruit juice increases the bioavailability of artemether
October 21, 2026
PQQ for Mitochondrial Rejuvenation and Skin Aging
October 13, 2026
Ciona robusta as a Marine Cosmetic Ingredient for Skin Hydration
October 13, 2026